
LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
Description
About LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
The Lymphocytic choriomeningitis virus (strain Armstrong) Pre-glycoprotein polyprotein GP complex Peptide (IEDB: 74978) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Pre-glycoprotein polyprotein GP complex Peptide, H-YLVSIFLHL-OH (Uniprot: P09991 aa: 447-455) from JPT is produced under strict quality control and quality management.
LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL - Specifications
- Peptide sequence: H-YLVSIFLHL-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
References:
Read References with JPT’s Antigen Peptides
LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL has been described in:
HLA-A2-restricted Protection against Lethal Lymphocytic Choriomeningitis, nan, 2007 (PMID: Submission)
HLA-A2-restricted protection against lethal lymphocytic choriomeningitis., J Virol, 2007 (PMID: 17166907)
Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules., Proc Natl Acad Sci U S A, 2018 (PMID: 30348802)
Documentation
Documentation for LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
Properties
Properties of LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Lymphocytic choriomeningitis virus |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to LCMV (strain Armstrong) Pre-glycoprotein polyprotein GP complex 447-455, YLVSIFLHL
Information | Values |
---|---|
Sequence: | H-YLVSIFLHL-OH |
Specifications: | 9mer peptide as TFA salt |